Table 2

Prescription audit of drug therapies in the study cohort

VariableNumbers with data
Total, men/women
Total (N=8699)Men (N=5292)Women (N=3407)χ2 test p value (male/female differences)
Antidiabetes drugs
 Insulin5023, 3053/1970794 (15.8)513 (16.8)281 (14.2)0.016
 Oral antidiabetics8699, 5292/34074229 (84.2)2772 (90.8)1457 (73.9)<0.001
Antihypertensive and other drugs
 Renin angiotensin system blockers8699, 5292/34073169 (36.4)1897 (35.8)1272 (37.3)0.159
 β-blockers6258, 3898/23601726 (27.6)1060 (27.2)666 (28.2)<0.001
 Calcium channel blockers4636, 2820/18161100 (23.7)601 (21.3)499 (27.5)<0.001
 Diuretics4515, 2733/17821438 (31.8)815 (29.8)623 (34.9)<0.001
 Antiplatelets6229, 4515/27332073 (33.3)1332 (29.5)741 (27.1)0.029
Lipid-lowering drugs
 Statins8699, 5292/34074802 (55.2)3026 (57.2)1776 (52.1)<0.001
 Fibrates3546, 2132/1414325 (9.2)209 (9.8)116 (8.2)0.106
Lipid-lowering drugs at level of care8699, 5292/3407
 Internists2301, 1261/10401227 (53.3)714 (56.6)513 (49.3)<0.001
 Diabetologists3299, 2215/10842126 (64.4)1424 (64.3)702 (64.3)0.791
 Endocrinologists3099, 1816/12831449 (46.8)888 (48.8)561 (43.7)0.004
Statins in various risk groups8699, 5292/3407
 Low risk1506, 940/566855 (56.8)539 (57.3)316 (55.8)0.567
 Medium risk5424, 3208/22162920 (53.8)1806 (56.3)1114 (50.3)<0.001
 High risk1769, 1144/6251027 (58.0)681 (59.5)346 (55.3)0.089
Statin types as percent of statin use4802, 3026/1776
 Atorvastatin3560 (74.1)2252 (74.4)1308 (73.6)0.554
 Rosuvastatin1098 (22.9)687 (22.7)411 (23.1)0.726
 Other statins144 (3.0)87 (2.9)57 (3.2)0.511
Statins dosage as percent of statin use4802, 3026/1776
 Low dose92 (1.9)54 (1.8)38 (2.1)0.386
 Moderate dose4100 (85.4)2580 (86.2)1520 (85.6)0.758
 High dose610 (12.7)392 (13.0)218 (12.3)0.497
  • Numbers in parentheses are percent; renin angiotensin system blockers include ACE inhibitors and angiotensin receptor blockers.